Skip to main content
Top
Published in: Annals of Hematology 2/2017

Open Access 01-02-2017 | Original Article

History of autoimmune disease is associated with impaired survival in multiple myeloma and monoclonal gammopathy of undetermined significance: a population-based study

Authors: Ebba K. Lindqvist, Ola Landgren, Sigrún H. Lund, Ingemar Turesson, Malin Hultcrantz, Lynn Goldin, Magnus Björkholm, Sigurdur Y. Kristinsson

Published in: Annals of Hematology | Issue 2/2017

Login to get access

Abstract

Multiple myeloma (MM) is a plasma cell disorder preceded by monoclonal gammopathy of undetermined significance (MGUS). Incidence of MM and MGUS is higher among patients with autoimmune disease. The aim of this study was to determine whether a history of autoimmunity has an impact on survival in MM and MGUS. Using high-quality national Swedish registries, we identified 8367 patients with MM, 18,768 patients with MGUS, and 110,251 matched control subjects, and obtained information on previous autoimmune disease in patients and controls. Cox regression was used to calculate hazard ratios (HRs) for overall survival with 95 % confidence intervals (CIs). In patients with MM and a prior autoimmune disease, the risk of death was significantly increased, HR = 1.2 (95 % CI 1.2–1.3) compared to MM patients with no history of autoimmunity. In MGUS patients, a prior autoimmune disease was associated with a significantly 1.4-fold elevated risk of death (95 % CI 1.3–1.4). When analyzing different types of autoimmune diseases, a history of ulcerative colitis had a stronger impact on survival in MM than in controls. Our findings that a history of autoimmune disease has a negative impact on survival in MM and MGUS could be due to shared underlying common genetic factors, or that patients with a history of autoimmunity develop more severe cases of MM and MGUS, or cumulative comorbidity in the individual. Our results suggest that more attention should be paid to comorbidity as a prognostic factor in MGUS and MM, and underlines the need for studies aimed at tailoring therapy according to comorbidity.
Appendix
Available only for authorised users
Literature
1.
go back to reference Swerdlov S, Campo E, Harris N, Jaffe E, Pileri S, Stein H, Thiele J, Vardiman J (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. IARC, Lyon Swerdlov S, Campo E, Harris N, Jaffe E, Pileri S, Stein H, Thiele J, Vardiman J (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. IARC, Lyon
2.
go back to reference Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, Fonseca R, Rajkumar SV, Offord JR, Larson DR, Plevak ME, Therneau TM, Greipp PR (2003) Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78:21–33CrossRefPubMed Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, Fonseca R, Rajkumar SV, Offord JR, Larson DR, Plevak ME, Therneau TM, Greipp PR (2003) Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78:21–33CrossRefPubMed
3.
go back to reference Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, Melton LJ 3rd (2002) A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 346:564–569CrossRefPubMed Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, Melton LJ 3rd (2002) A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 346:564–569CrossRefPubMed
4.
go back to reference Vachon CM, Kyle RA, Therneau TM, Foreman BJ, Larson DR, Colby CL, Phelps TK, Dispenzieri A, Kumar SK, Katzmann JA, Rajkumar SV (2009) Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance; Blood. United States 114:785–790 Vachon CM, Kyle RA, Therneau TM, Foreman BJ, Larson DR, Colby CL, Phelps TK, Dispenzieri A, Kumar SK, Katzmann JA, Rajkumar SV (2009) Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance; Blood. United States 114:785–790
5.
go back to reference Landgren O, Linet MS, McMaster ML, Gridley G, Hemminki K, Goldin LR (2006) Familial characteristics of autoimmune and hematologic disorders in 8,406 multiple myeloma patients: a population-based case-control study. Int J Cancer 118:3095–3098CrossRefPubMed Landgren O, Linet MS, McMaster ML, Gridley G, Hemminki K, Goldin LR (2006) Familial characteristics of autoimmune and hematologic disorders in 8,406 multiple myeloma patients: a population-based case-control study. Int J Cancer 118:3095–3098CrossRefPubMed
6.
go back to reference Landgren O, Kristinsson SY, Goldin LR, Caporaso NE, Blimark C, Mellqvist UH, Wahlin A, Bjorkholm M, Turesson I (2009) Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden. Blood 114:791–795CrossRefPubMedPubMedCentral Landgren O, Kristinsson SY, Goldin LR, Caporaso NE, Blimark C, Mellqvist UH, Wahlin A, Bjorkholm M, Turesson I (2009) Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden. Blood 114:791–795CrossRefPubMedPubMedCentral
7.
go back to reference Kristinsson SY, Bjorkholm M, Goldin LR, Blimark C, Mellqvist UH, Wahlin A, Turesson I, Landgren O (2009) Patterns of hematologic malignancies and solid tumors among 37,838 first-degree relatives of 13,896 patients with multiple myeloma in Sweden. Int J Cancer 125:2147–2150CrossRefPubMedPubMedCentral Kristinsson SY, Bjorkholm M, Goldin LR, Blimark C, Mellqvist UH, Wahlin A, Turesson I, Landgren O (2009) Patterns of hematologic malignancies and solid tumors among 37,838 first-degree relatives of 13,896 patients with multiple myeloma in Sweden. Int J Cancer 125:2147–2150CrossRefPubMedPubMedCentral
8.
go back to reference Landgren O, Weiss BM (2009) Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis. Leukemia 23:1691–1697CrossRefPubMed Landgren O, Weiss BM (2009) Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis. Leukemia 23:1691–1697CrossRefPubMed
9.
go back to reference Landgren O, Gridley G, Turesson I, Caporaso NE, Goldin LR, Baris D, Fears TR, Hoover RN, Linet MS (2006) Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood 107:904–906CrossRefPubMedPubMedCentral Landgren O, Gridley G, Turesson I, Caporaso NE, Goldin LR, Baris D, Fears TR, Hoover RN, Linet MS (2006) Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood 107:904–906CrossRefPubMedPubMedCentral
10.
go back to reference Landgren O, Kyle RA, Hoppin JA, Beane Freeman LE, Cerhan JR, Katzmann JA, Rajkumar SV, Alavanja MC (2009) Pesticide exposure and risk of monoclonal gammopathy of undetermined significance in the Agricultural Health Study. Blood 113:6386–6391CrossRefPubMedPubMedCentral Landgren O, Kyle RA, Hoppin JA, Beane Freeman LE, Cerhan JR, Katzmann JA, Rajkumar SV, Alavanja MC (2009) Pesticide exposure and risk of monoclonal gammopathy of undetermined significance in the Agricultural Health Study. Blood 113:6386–6391CrossRefPubMedPubMedCentral
11.
go back to reference Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, Dispenzieri A, Katzmann JA, Melton LJ 3rd (2006) Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 354:1362–1369CrossRefPubMed Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, Dispenzieri A, Katzmann JA, Melton LJ 3rd (2006) Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 354:1362–1369CrossRefPubMed
12.
go back to reference Landgren O, Shim YK, Michalek J, Costello R, Burton D, Ketchum N, Calvo KR, Caporaso N, Raveche E, Middleton D, Marti G, Vogt RF Jr (2015) Agent orange exposure and monoclonal gammopathy of undetermined significance: an Operation Ranch Hand Veteran Cohort Study. JAMA Oncol 1:1061–1068CrossRefPubMed Landgren O, Shim YK, Michalek J, Costello R, Burton D, Ketchum N, Calvo KR, Caporaso N, Raveche E, Middleton D, Marti G, Vogt RF Jr (2015) Agent orange exposure and monoclonal gammopathy of undetermined significance: an Operation Ranch Hand Veteran Cohort Study. JAMA Oncol 1:1061–1068CrossRefPubMed
13.
go back to reference Forabosco P, Bouzigon E, Ng MY, Hermanowski J, Fisher SA, Criswell LA, Lewis CM (2009) Meta-analysis of genome-wide linkage studies across autoimmune diseases. Eur J Hum Genet 17:236–243CrossRefPubMed Forabosco P, Bouzigon E, Ng MY, Hermanowski J, Fisher SA, Criswell LA, Lewis CM (2009) Meta-analysis of genome-wide linkage studies across autoimmune diseases. Eur J Hum Genet 17:236–243CrossRefPubMed
14.
go back to reference Zhernakova A, van Diemen CC, Wijmenga C (2009) Detecting shared pathogenesis from the shared genetics of immune-related diseases. Nat Rev Genet 10:43–55CrossRefPubMed Zhernakova A, van Diemen CC, Wijmenga C (2009) Detecting shared pathogenesis from the shared genetics of immune-related diseases. Nat Rev Genet 10:43–55CrossRefPubMed
16.
go back to reference Landgren AM, Landgren O, Gridley G, Dores GM, Linet MS, Morton LM (2011) Autoimmune disease and subsequent risk of developing alimentary tract cancers among 4.5 million US male veterans. Cancer 117:1163–1171CrossRefPubMed Landgren AM, Landgren O, Gridley G, Dores GM, Linet MS, Morton LM (2011) Autoimmune disease and subsequent risk of developing alimentary tract cancers among 4.5 million US male veterans. Cancer 117:1163–1171CrossRefPubMed
17.
go back to reference Hemminki K, Liu X, Ji J, Sundquist J, Sundquist K (2012) Effect of autoimmune diseases on mortality and survival in subsequent digestive tract cancers. Ann Oncol 23:2179–2184CrossRefPubMed Hemminki K, Liu X, Ji J, Sundquist J, Sundquist K (2012) Effect of autoimmune diseases on mortality and survival in subsequent digestive tract cancers. Ann Oncol 23:2179–2184CrossRefPubMed
18.
go back to reference Hemminki K, Liu X, Ji J, Sundquist J, Sundquist K (2012) Effect of autoimmune diseases on risk and survival in histology-specific lung cancer. Eur Respir J 40:1489–1495CrossRefPubMed Hemminki K, Liu X, Ji J, Sundquist J, Sundquist K (2012) Effect of autoimmune diseases on risk and survival in histology-specific lung cancer. Eur Respir J 40:1489–1495CrossRefPubMed
19.
go back to reference Hemminki K, Liu X, Ji J, Sundquist J, Sundquist K (2012) Kaposi sarcoma and Merkel cell carcinoma after autoimmune disease. Int J Cancer 131:E326–E328CrossRefPubMed Hemminki K, Liu X, Ji J, Sundquist J, Sundquist K (2012) Kaposi sarcoma and Merkel cell carcinoma after autoimmune disease. Int J Cancer 131:E326–E328CrossRefPubMed
20.
go back to reference Lindqvist EK, Goldin LR, Landgren O, Blimark C, Mellqvist UH, Turesson I, Wahlin A, Bjorkholm M, Kristinsson SY (2011) Personal and family history of immune-related conditions increase the risk of plasma cell disorders: a population-based study. Blood 118:6284–6291CrossRefPubMedPubMedCentral Lindqvist EK, Goldin LR, Landgren O, Blimark C, Mellqvist UH, Turesson I, Wahlin A, Bjorkholm M, Kristinsson SY (2011) Personal and family history of immune-related conditions increase the risk of plasma cell disorders: a population-based study. Blood 118:6284–6291CrossRefPubMedPubMedCentral
21.
go back to reference Brown LM, Gridley G, Check D, Landgren O (2008) Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders. Blood 111:3388–3394CrossRefPubMedPubMedCentral Brown LM, Gridley G, Check D, Landgren O (2008) Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders. Blood 111:3388–3394CrossRefPubMedPubMedCentral
22.
go back to reference Hemminki K, Liu X, Forsti A, Ji J, Sundquist J, Sundquist K (2012) Effect of autoimmune diseases on incidence and survival in subsequent multiple myeloma. J Hematol Oncol 5:59CrossRefPubMedPubMedCentral Hemminki K, Liu X, Forsti A, Ji J, Sundquist J, Sundquist K (2012) Effect of autoimmune diseases on incidence and survival in subsequent multiple myeloma. J Hematol Oncol 5:59CrossRefPubMedPubMedCentral
23.
go back to reference Walsh SJ, Rau LM (2000) Autoimmune diseases: a leading cause of death among young and middle-aged women in the United States. Am J Public Health 90:1463–1466CrossRefPubMedPubMedCentral Walsh SJ, Rau LM (2000) Autoimmune diseases: a leading cause of death among young and middle-aged women in the United States. Am J Public Health 90:1463–1466CrossRefPubMedPubMedCentral
24.
go back to reference Thomas SL, Griffiths C, Smeeth L, Rooney C, Hall AJ (2010) Burden of mortality associated with autoimmune diseases among females in the United Kingdom. Am J Public Health 100:2279–2287CrossRefPubMedPubMedCentral Thomas SL, Griffiths C, Smeeth L, Rooney C, Hall AJ (2010) Burden of mortality associated with autoimmune diseases among females in the United Kingdom. Am J Public Health 100:2279–2287CrossRefPubMedPubMedCentral
25.
go back to reference Landgren O, Pfeiffer RM, Kristinsson SY, Bjorkholm M (2010) Survival patterns in patients with Hodgkin’s lymphoma with a pre-existing hospital discharge diagnosis of autoimmune disease. J Clin Oncol 28:5081–5087CrossRefPubMedPubMedCentral Landgren O, Pfeiffer RM, Kristinsson SY, Bjorkholm M (2010) Survival patterns in patients with Hodgkin’s lymphoma with a pre-existing hospital discharge diagnosis of autoimmune disease. J Clin Oncol 28:5081–5087CrossRefPubMedPubMedCentral
26.
go back to reference Swedish National Board of Health and Welfare. Svenska cancerregistret. Socialstyrelsen, Stockholm, Sweden Swedish National Board of Health and Welfare. Svenska cancerregistret. Socialstyrelsen, Stockholm, Sweden
27.
go back to reference Turesson I, Linet MS, Bjorkholm M, Kristinsson SY, Goldin LR, Caporaso NE, Landgren O (2007) Ascertainment and diagnostic accuracy for hematopoietic lymphoproliferative malignancies in Sweden 1964-2003. Int J Cancer 121:2260–2266CrossRefPubMed Turesson I, Linet MS, Bjorkholm M, Kristinsson SY, Goldin LR, Caporaso NE, Landgren O (2007) Ascertainment and diagnostic accuracy for hematopoietic lymphoproliferative malignancies in Sweden 1964-2003. Int J Cancer 121:2260–2266CrossRefPubMed
28.
go back to reference Nilsson A, Spetz C, Carsjo K, Nightingale R, Smedby B (1994) Slutenvårdsregistrets tillförlitlighet. Lakartidningen 91:598–605PubMed Nilsson A, Spetz C, Carsjo K, Nightingale R, Smedby B (1994) Slutenvårdsregistrets tillförlitlighet. Lakartidningen 91:598–605PubMed
29.
go back to reference Swedish National Board of Health and Welfare. Patientregistret. Socialstyrelsen, Stockholm, Sweden Swedish National Board of Health and Welfare. Patientregistret. Socialstyrelsen, Stockholm, Sweden
30.
go back to reference Kristinsson SY, Koshiol J, Bjorkholm M, Goldin LR, McMaster ML, Turesson I, Landgren O (2010) Immune-related and inflammatory conditions and risk of lymphoplasmacytic lymphoma or Waldenstrom macroglobulinemia. J Natl Cancer Inst 102:557–567CrossRefPubMedPubMedCentral Kristinsson SY, Koshiol J, Bjorkholm M, Goldin LR, McMaster ML, Turesson I, Landgren O (2010) Immune-related and inflammatory conditions and risk of lymphoplasmacytic lymphoma or Waldenstrom macroglobulinemia. J Natl Cancer Inst 102:557–567CrossRefPubMedPubMedCentral
31.
go back to reference Rajkumar SV, Kyle RA, Buadi FK (2010) Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence. Mayo Clin Proc 85:945–948CrossRefPubMedPubMedCentral Rajkumar SV, Kyle RA, Buadi FK (2010) Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence. Mayo Clin Proc 85:945–948CrossRefPubMedPubMedCentral
32.
go back to reference Turesson I, Velez R, Kristinsson SY, Landgren O (2010) Patterns of multiple myeloma during the past 5 decades: stable incidence rates for all age groups in the population but rapidly changing age distribution in the clinic. Mayo Clin Proc 85:225–230CrossRefPubMedPubMedCentral Turesson I, Velez R, Kristinsson SY, Landgren O (2010) Patterns of multiple myeloma during the past 5 decades: stable incidence rates for all age groups in the population but rapidly changing age distribution in the clinic. Mayo Clin Proc 85:225–230CrossRefPubMedPubMedCentral
33.
go back to reference Palumbo A, Bringhen S, Ludwig H, Dimopoulos MA, Blade J, Mateos MV, Rosinol L, Boccadoro M, Cavo M, Lokhorst H, Zweegman S, Terpos E, Davies F, Driessen C, Gimsing P, Gramatzki M, Hajek R, Johnsen HE, Leal Da Costa F, Sezer O, Spencer A, Beksac M, Morgan G, Einsele H, San Miguel JF, Sonneveld P (2011) Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood 118:4519–4529CrossRefPubMed Palumbo A, Bringhen S, Ludwig H, Dimopoulos MA, Blade J, Mateos MV, Rosinol L, Boccadoro M, Cavo M, Lokhorst H, Zweegman S, Terpos E, Davies F, Driessen C, Gimsing P, Gramatzki M, Hajek R, Johnsen HE, Leal Da Costa F, Sezer O, Spencer A, Beksac M, Morgan G, Einsele H, San Miguel JF, Sonneveld P (2011) Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood 118:4519–4529CrossRefPubMed
34.
go back to reference Kleber M, Ihorst G, Gross B, Koch B, Reinhardt H, Wasch R, Engelhardt M (2013) Validation of the Freiburg comorbidity index in 466 multiple myeloma patients and combination with the international staging system are highly predictive for outcome. Clin Lymphoma Myeloma Leuk 3(5):541–551CrossRef Kleber M, Ihorst G, Gross B, Koch B, Reinhardt H, Wasch R, Engelhardt M (2013) Validation of the Freiburg comorbidity index in 466 multiple myeloma patients and combination with the international staging system are highly predictive for outcome. Clin Lymphoma Myeloma Leuk 3(5):541–551CrossRef
35.
go back to reference Kleber M, Ihorst G, Terhorst M, Koch B, Deschler B, Wasch R, Engelhardt M (2011) Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM-comorbidity score. Blood Cancer J 1:e35CrossRefPubMedPubMedCentral Kleber M, Ihorst G, Terhorst M, Koch B, Deschler B, Wasch R, Engelhardt M (2011) Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM-comorbidity score. Blood Cancer J 1:e35CrossRefPubMedPubMedCentral
36.
go back to reference Offidani M, Corvatta L, Polloni C, Centurioni R, Visani G, Brunori M, Gentili S, Catarini M, Samori A, Blasi N, Alesiani F, Caraffa P, Burattini M, Galieni P, Fraticelli P, Ferranti M, Giuliodori L, Leoni P (2012) Assessment of vulnerability measures and their effect on survival in a real-life population of multiple myeloma patients registered at Marche Region Multiple Myeloma Registry. Clin Lymphoma Myeloma Leuk 12:423–432CrossRefPubMed Offidani M, Corvatta L, Polloni C, Centurioni R, Visani G, Brunori M, Gentili S, Catarini M, Samori A, Blasi N, Alesiani F, Caraffa P, Burattini M, Galieni P, Fraticelli P, Ferranti M, Giuliodori L, Leoni P (2012) Assessment of vulnerability measures and their effect on survival in a real-life population of multiple myeloma patients registered at Marche Region Multiple Myeloma Registry. Clin Lymphoma Myeloma Leuk 12:423–432CrossRefPubMed
37.
go back to reference Kleber M, Ihorst G, Deschler B, Jakob C, Liebisch P, Koch B, Sezer O, Engelhardt M (2009) Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients. Eur J Haematol 83:519–527CrossRefPubMed Kleber M, Ihorst G, Deschler B, Jakob C, Liebisch P, Koch B, Sezer O, Engelhardt M (2009) Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients. Eur J Haematol 83:519–527CrossRefPubMed
38.
go back to reference Farina L, Bruno B, Patriarca F, Spina F, Sorasio R, Morelli M, Fanin R, Boccadoro M, Corradini P (2009) The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation. Leukemia 23:1131–1138CrossRefPubMed Farina L, Bruno B, Patriarca F, Spina F, Sorasio R, Morelli M, Fanin R, Boccadoro M, Corradini P (2009) The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation. Leukemia 23:1131–1138CrossRefPubMed
39.
go back to reference Falco P, Cavallo F, Larocca A, Rossi D, Guglielmelli T, Rocci A, Grasso M, Siez ML, De Paoli L, Oliva S, Molica S, Mina R, Gay F, Benevolo G, Musto P, Omede P, Freilone R, Bringhen S, Carella AM, Gaidano G, Boccadoro M, Palumbo A (2013) Lenalidomide-prednisone induction followed by lenalidomide-melphalan-prednisone consolidation and lenalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma patients. Leukemia 27:695–701CrossRefPubMed Falco P, Cavallo F, Larocca A, Rossi D, Guglielmelli T, Rocci A, Grasso M, Siez ML, De Paoli L, Oliva S, Molica S, Mina R, Gay F, Benevolo G, Musto P, Omede P, Freilone R, Bringhen S, Carella AM, Gaidano G, Boccadoro M, Palumbo A (2013) Lenalidomide-prednisone induction followed by lenalidomide-melphalan-prednisone consolidation and lenalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma patients. Leukemia 27:695–701CrossRefPubMed
40.
go back to reference Kristinsson SY, Landgren O, Dickman PW, Derolf AR, Bjorkholm M (2007) Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol 25:1993–1999CrossRefPubMed Kristinsson SY, Landgren O, Dickman PW, Derolf AR, Bjorkholm M (2007) Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol 25:1993–1999CrossRefPubMed
41.
go back to reference Turesson I, Velez R, Kristinsson SY, Landgren O (2010) Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study. J Clin Oncol 28:830–834CrossRefPubMed Turesson I, Velez R, Kristinsson SY, Landgren O (2010) Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study. J Clin Oncol 28:830–834CrossRefPubMed
42.
go back to reference Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, Kapoor P, Dingli D, Hayman SR, Leung N, Lust J, McCurdy A, Russell SJ, Zeldenrust SR, Kyle RA, Rajkumar SV (2013) Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 28(5):1122–1128CrossRefPubMedPubMedCentral Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, Kapoor P, Dingli D, Hayman SR, Leung N, Lust J, McCurdy A, Russell SJ, Zeldenrust SR, Kyle RA, Rajkumar SV (2013) Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 28(5):1122–1128CrossRefPubMedPubMedCentral
43.
go back to reference Kristinsson SY, Anderson WF, Landgren O (2014) Improved long-term survival in multiple myeloma up to the age of 80 years. Leukemia 28(6):1346CrossRefPubMed Kristinsson SY, Anderson WF, Landgren O (2014) Improved long-term survival in multiple myeloma up to the age of 80 years. Leukemia 28(6):1346CrossRefPubMed
Metadata
Title
History of autoimmune disease is associated with impaired survival in multiple myeloma and monoclonal gammopathy of undetermined significance: a population-based study
Authors
Ebba K. Lindqvist
Ola Landgren
Sigrún H. Lund
Ingemar Turesson
Malin Hultcrantz
Lynn Goldin
Magnus Björkholm
Sigurdur Y. Kristinsson
Publication date
01-02-2017
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 2/2017
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-016-2859-8

Other articles of this Issue 2/2017

Annals of Hematology 2/2017 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.